(272 days)
The Focal One device is indicated for transrectal high intensity focused ultrasound (HIFU) ablation of prostate tissue.
The Focal One® is an evolution from the previous generation device, designed by EDAP: Ablatherm Integrated Imaging (K153023) and Ablatherm Fusion (K172285). The Focal One® consists of the Focal One® module with a software control system, an endorectal dynamic focusing probe, a leg holder, a set of single use disposables and a coupling liquid pouch.
The Focal One® module consists of a motorized and manual endorectal dynamic focusing probe positioning unit, a RF amplifier to power the transducer, a computer to control device operation, a cooling system to cool Ablasonic (coupling liquid) and built-in safety features. It also allows the user to control the treatment while providing different user interfaces: two dual touch-screens, mouse, keyboard and printer. The Focal One® energy is delivered via an endorectal dynamic focusing probe, which includes an imaging system. The high-energy ultrasound waves propagate through the rectal wall and are focused on a portion of the prostate, generating intense heat and causing the ablation of tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues within the prostate. The endorectal dynamic focusing probe is attached to a support, enabling movements in the longitudinal, transverse, vertical and angular directions, and in rotation. A coupling liquid pouch (Ablasonic®) included in the FocalPak disposable kit, attached to a stand, maintained at a controlled temperature flows continuously (via a peristaltic pump) into the balloon to preserve the rectal wall from heating associated with the treatment. The module is mounted on four multidirectional wheels allowing an easy positioning of the device in the treatment room.
The document describes the Focal One device, a high-intensity focused ultrasound (HIFU) system for prostate tissue ablation, and its substantial equivalence to predicate devices (Ablatherm Integrated Imaging and Sonablate) for 510(k) clearance. The provided text, however, does not contain a specific table detailing "acceptance criteria" for the device's performance followed by reported device performance against those criteria. Instead, it presents clinical data as evidence for the device's safety and effectiveness to support substantial equivalence.
Based on the information provided in the document, here's an attempt to answer your request, focusing on the evidence presented to demonstrate the device's performance, even without a formal "acceptance criteria table":
The study described is a clinical report summarizing data on subjects treated with the Focal One® HIFU device to provide evidence of the safety and effectiveness of the ablation of prostate tissue.
1. A table of acceptance criteria and the reported device performance
As mentioned, the document does not explicitly state predetermined "acceptance criteria" in a table format that the device had to meet. However, it presents clinical outcomes that serve as performance metrics to demonstrate efficacy and safety. These would implicitly be the "performance targets" or "evidence of effectiveness" that the FDA considered acceptable for substantial equivalence.
Here's an interpretation of the performance metrics and the reported device performance:
| Performance Metric (Implicit Acceptance Criteria) | Reported Device Performance (Clinical Study Results) |
|---|---|
| Prostate Volume Reduction | Demonstrate significant reduction in prostate volume post-HIFU. Reported: Prostate volume reduced from 49.8 ± 23.1 mL (median 44.0 mL) to 38.6 ± 25.5 mL (median 31.5 mL) for paired cases (n=78). This represents a 22.7% reduction (95% CI 17.6%; 27.8%), with p<0.001. |
| PSA Reduction (Evidence of Ablation) | Demonstrate significant reduction and stability of Prostate-Specific Antigen (PSA) levels post-HIFU. Reported: - Mean PSA reduction at 6 months: -3.7 ng/mL (95% CI -4.3; -3.1), statistically significant (p<0.001). - Percentage PSA reduction at 6 months: -53.0% (95% CI -60.2; -45.8). - Mean PSA reduction at 12 months: -3.7 ng/mL (95% CI -4.2; -3.1), statistically significant (p<0.001). - Percentage PSA reduction at 12 months: -54.4% (95% CI -60.2; -48.6). - Mean PSA nadir: 2.2 ± 1.6 ng/mL, reached around 8 months. - PSA velocity: -0.57 ± 5.30 ng/mL/year (med. 0.018 ng/mL/year). |
| Histological Evidence of Tissue Ablation | Demonstrate negative biopsy rates in the targeted area post-HIFU. Reported: Negative biopsy rate at the level of the targeted area of 63% (95% CI 53.5%; 72.5%) for 97 of 100 subjects who underwent biopsy. (Subjects who did not undergo control biopsies were considered positive for this analysis). |
| Safety Profile (Adverse Events) | Demonstrate an acceptable safety profile, consistent with predicate devices for HIFU prostate ablation. Reported: List of adverse events collected, showing occurrences in subjects (e.g., Erectile Dysfunction: 45%; Urinary Tract Infection: 30%, etc.). The majority of adverse events resolved, with some exceptions (erectile dysfunction, urinary dysfunction). The data was audited by a third-party CRO. |
2. Sample size used for the test set and the data provenance
- Sample Size: Data from 100 subjects were included in the clinical report.
- Data Provenance:
- Country of Origin: Four prospective clinical trials conducted in Europe.
- Retrospective or Prospective: A retrospective analysis of prospective clinical studies.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not specify the number or qualifications of experts used to establish the ground truth for the test set. It mentions prostate volume assessment by MRI, PSA measurements, and biopsy results, which are common clinical methods, but no details on expert consensus for these measurements are provided.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
The document does not describe an adjudication method for the test set. Data was collected through routine clinical evaluations (MRI, PSA, biopsies). The adverse event data was audited by a third-party CRO to verify reliability and completeness.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
No. This was not a study evaluating human reader performance with or without AI assistance. The Focal One is a treatment device, not an image interpretation or diagnostic AI device.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
The Focal One is a treatment device operated by a human. Its performance is assessed as a system in clinical use, not as a standalone algorithm without human involvement. Bench testing was done for ablative performance (beam steering, acoustical parameters), and animal studies confirmed ablative performance in living tissue. These are technical evaluations, not an "algorithm only" performance assessment in the context of clinical decision-making.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
The ground truth or evidence of efficacy was established through a combination of:
- Clinical Outcomes Data:
- Quantitative measurements: Prostate volume reduction (assessed by MRI).
- Biochemical markers: PSA reduction and stability.
- Histological evidence: Prostate biopsy results (confirming tissue ablation).
- Patient Outcomes: Adverse event collection to assess safety.
8. The sample size for the training set
This document describes a clinical study to demonstrate the safety and effectiveness of the Focal One device itself, not a study for an AI algorithm that would typically have a distinct training set. Therefore, there is no mention of a "training set" sample size in the context of AI model development.
9. How the ground truth for the training set was established
As there is no mention of a training set for an AI model, this question is not applicable to the provided document. The clinical data collected serves as evidence of the device's performance.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA text logo on the right. The FDA text logo is in blue and includes the words "FDA U.S. FOOD & DRUG" in a larger font size, with "ADMINISTRATION" written below in a smaller font size.
June 7, 2018
EDAP Technomed, Inc. Hugo Embert CEO 5321 Industrial Oaks Blvd., Suite 110 Austin, TX 78735
Re: K172721 Trade/Device Name: Focal One Regulation Number: 21 CFR§ 876.4340 Regulation Name: High Intensity Ultrasound System for Prostate Tissue Ablation Regulatory Class: II Product Code: PLP Dated: May 7, 2018 Received: May 7, 2018
Dear Hugo Embert:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
{1}------------------------------------------------
You must comply with all the Act's requirements. including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Joyce M. Whang -S
for
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
VI. INDICATIONS FOR USE STATEMENT
EDAP Technomed Inc's Indications for Use Statement for modified Focal One® is provided on the following page.
| DEPARTMENT OF HEALTH AND HUMAN SERVICES | Form Approved: OMB No. 0910-0120 |
|---|---|
| Food and Drug Administration | Expiration Date: 06/30/2020 |
| Indications for Use | See PRA Statement below. |
| 510(k) Number (if known) | K172721 |
|---|---|
| Device Name | FOCAL ONE |
| Indications for Use (Describe) | The Focal One device is indicated for transrectal high intensity focused ultrasound (HIFU) ablation of prostate tissue. |
| Type of Use (Select one or both, as applicable) | Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
FORM FDA 3881 (7/17)
11 00/04/20 (1)(C) 00/04/2019 00 111
{3}------------------------------------------------
510(k) SUMMARY
EDAP Technomed, Inc 5321 Industrial Oaks Blvd, Suite 110 AUSTIN, TX 78735 USA Phone: 512 832 7956 Facsimile: 512 684 1313
Contact Person: Matthew Hull
Date Prepared: June 7, 2018
| Proprietary Name: | Focal One® |
|---|---|
| Common Name: | High intensity ultrasound system for prostate tissue ablation |
| Regulatory Class: | II |
| Regulation: | 21 CFR 876.4340 |
| Regulation Name: | High intensity ultrasound system for prostate tissue ablation |
| Product Code: | PLP |
| Predicate Device(s): | Ablatherm Integrated Imaging (K153023), Sonablate (K160942) |
| Reference Device(s): | Ablatherm Fusion (K172285) |
| Intended Use: |
The Focal One® device is indicated for transrectal high intensity focused ultrasound (HIFU) ablation of prostate tissue.
Device Description:
The Focal One® is an evolution from the previous generation device, designed by EDAP: Ablatherm Integrated Imaging (K153023) and Ablatherm Fusion (K172285). The Focal One® consists of the Focal One® module with a software control system, an endorectal dynamic focusing probe, a leg holder, a set of single use disposables and a coupling liquid pouch.
The Focal One® module consists of a motorized and manual endorectal dynamic focusing probe positioning unit, a RF amplifier to power the transducer, a computer to control device operation, a cooling system to cool Ablasonic (coupling liquid) and built-in safety features. It also allows the user to control the treatment while providing different user interfaces: two dual touch-screens, mouse, keyboard and printer. The Focal One® energy is delivered via an endorectal dynamic focusing probe, which includes an imaging system. The high-energy ultrasound waves propagate through the rectal wall and are focused on a portion of the prostate, generating intense heat and causing the ablation of tissue within the focal area. The process is then repeated in a stepwise fashion to destroy the targeted tissues within the prostate. The endorectal dynamic focusing probe is attached to a support, enabling movements in the longitudinal, transverse, vertical and angular directions, and in rotation. A coupling liquid pouch (Ablasonic®) included in the FocalPak disposable kit, attached to a stand, maintained at a controlled temperature flows continuously (via a peristaltic pump) into the balloon to preserve the rectal wall from heating associated with the treatment. The module is mounted on four multidirectional wheels allowing an easy positioning of the device in the treatment room.
Non-Clinical Testing
The following non-clinical testing was provided in support of this submission:
- . Sterilization and Shelf Life
{4}------------------------------------------------
- Biocompatibility ●
- Software Documentation
- Electrical Safety and Electromagnetic Compatibility
- IEC 60601-2-62: Medical electrical equipment Part 2 62 Particular requirements for the basic safety and essential performance of high intensity therapeutic ultrasound HITU equipment.
- . Bench Testing to assess the ablative performance (beam steering technology, acoustical parameters) of Focal One.
Animal Studies on rabbit and pig models to confirm the ablative performance on the living tissue (dimensions, position of lesions and preservation of surrounding tissue).
Conformance to Recognized Standards
The Focal One® conforms to applicable sections of the following recognized consensus standards:
- . ISO 10993-1, biological evaluation of medical devices - part 1: Evaluation and testing within a risk management process.
- ISO 10993-5, Biological Evaluation Of Medical Devices: Test for in vitro cytotoxicity
- ISO 10993-10, Biological evaluation of medical devices part 10: tests for irritation and skin ● sensitization
- . IEC 60601-1:2005- Corr 1:2006, Corr 2:2007, Medical Electrical Equipment - Part 1: General Requirements For Safety
- IEC 60601-1-2:2014, Medical Electrical Equipment Part 1-2: General Requirements For Safety -● Collateral Standard: Electromagnetic Compatibility - Requirements And Test
- . IEC 62304: 2006/AC: 2006. Medical device software-Software life cycle processes.
- IEC 60601-2-62:1.0 2013-07, medical electrical equipment; part 2-62; particular requirements for the basic safety and essential performance of high intensity therapeutic ultrasound (hitu) equipment.
- . AAMI TIR12:2010 - Designing, testing, and labeling reusable medical devices for reprocessing in health care facilities: A guide for medical device manufacturer
- . AAMI TIR30:2011 - A compendium of processes, materials, test methods, and acceptance criteria for cleaning reusable medical devices,
- ANSI/AAMI ST81:2004/(R)2010 - Sterilization of medical devices - Information to be provided by the manufacturer for the processing of resterilizable medical devices
- ISO 17664:2004 - Sterilization of medical devices - Information to be provided by the manufacturer for the processing of resterilizable medical devices.
Clinical Data
A clinical report summarizing data on subjects treated with the Focal One® High Intensity Focused Ultrasound (HIFU) device to provide evidence of the safety and effectiveness of the ablation of prostate tissue has been provided in support of this submission. The EDAP data collection is a retrospective analysis of prospective clinical studies that demonstrates the efficacy of Focal One® HIFU supported by targeted volume and PSA reduction data and through prostate biopsies data.
This clinical report includes data from 100 subjects treated with Focal One® HIFU in four prospective clinical trials conducted in Europe. Despite the data having been collected in four separate studies, the patients in each trial had similar baseline and demographic characteristics, and all trials shared the same treatment approach (i.e., focal treatment of prostate tissue).. The studies were conducted primarily in sequential order over a period of 37 months which allowed for cumulative user group experience over time.
All subjects were treated with the commercial version of the device, demonstrating that the device performs as intended under anticipated conditions of use. Within the set of clinical trials presented, all selected
{5}------------------------------------------------
subjects were evaluated prior to the study procedure and then followed at 3 months, 12 months, 18 months and 24 months post-HIFU.
Evidence of prostate tissue ablation was provided through post-HIFU evaluation of targeted volume, PSA reduction and stability as well as biopsy results. All adverse events were collected regardless of their relationship to the HIFU procedure. The majority of adverse events resolved with the exception of some cases of erectile dysfunction and urinary dysfunction.
Prostate volume reduction
Within the entire population of subjects considered in this analysis, after the focal HIFU treatment, the prostate volume, assessed by MRI changed significantly. For paired cases (subjects for which MRI data are available at baseline and measurement point) (78 subjects), it went from 49.8 ± 23.1 mL (median 44.0 mL) to 38.6 ± 25.5 mL (median 31.5 mL) (p<0.001). This represents a 22.7% reduction (95% confidence interval 17.6%; 27.8%).
PSA reduction Following Focal HIFU Procedure
PSA reduction is also presented as supporting evidence of ablation. Ninety-nine subjects presented some reduction of PSA during the follow-up phase.
PSA reductions from baseline to 6 and 12 months are presented in the table below. As shown in this table, the mean PSA reductions are statistically significant at both 6 months (p<0.001) and 12 months (p<0.001).
| Variable | N | Mean | 95% CI | Significance ofreduction |
|---|---|---|---|---|
| PSA reduction at 6months (ng/mL) | 93 | -3.7 | - 4.3; - 3.1 | < 0.001 |
| Percentage PSAreduction at 6months (%) | 93 | - 53.0 | - 60.2; - 45.8 | |
| PSA reduction at12 months(ng/mL) | 82 | -3.7 | - 4.2; - 3.1 | < 0.001 |
| Percentage PSAreduction at 12months (%) | 82 | - 54.4 | - 60.2; - 48.6 |
The PSA nadir (lowest value measured during window of PSA assessment) is reached around 8 months after HIFU (mean nadir time achievement: 8.4 ± 6.3 months) with a median at 6.2. The mean PSA nadir is 2.2 ± 1.6 ng/ mL, with a median of 2.0 ng/mL.
In addition, in the analyzed population, the PSA velocity from first PSA assessment after HIFU procedure, to last not censured PSA measure performed, is - 0.57 ± 5.30 ng/mL/year (median 0.018 ng/mL/year) (see table below).
| Variable | N | Mean | 95% CI |
|---|---|---|---|
| PSA velocityng/ml/year | 96 | - 0.57 ng/mL/year | - 1.65, 0.50 |
PSA reduction and subsequent stability provides additional evidence of prostate tissue ablation.
{6}------------------------------------------------
Histological evidence of tissue ablation
In the set of selected clinical trials presented, during the study, treatment outcome was monitored: a multiparametric MRI was performed, followed by a series of prostatic biopsies allowing the distinction between HIFU targeted area and not targeted area outcomes. Ninety-seven of the 100 subjects underwent biopsy. In the present data collection analysis, subjects who did not undergo control biopsies, in the duration of their follow-up in their respective study, were considered as positive.
This corresponds to a negative biopsy rate at the level of the targeted area of 63% (95% confidence interval 53.5%; 72.5%) (see table below).
| Number of subjects | Negative Biopsy(1) | % | Positive Biopsy(2) | % |
|---|---|---|---|---|
| 100 | 63 | 63.0 | 37 | 37.0 |
(1) Negative biopsy in targeted area. (2) Positive biopsy in targeted area or missing biopsy (3 in total) (noncompliance).
Based on the analysis of the post-HIFU prostate volume evolution, the PSA reduction and the control biopsies, results provide evidence of the effectiveness of the Focal One® device in ablating specifically prostate tissue.
The information below provides a detailed view of the adverse events reported during the European prospective clinical studies evaluating the focal treatment of the Focal One which were submitted as evidence of the safety and effectiveness of the ablation of prostate tissue. Given the retrospective nature of the 510(k) clinical data, a third party CRO audited the adverse event tabulations to verify the reliability and completeness of the data collection.
| Adverse Event | Any Occurrence# Events (% Subjects)(n=100) |
|---|---|
| Any | 237 (79%) |
| Erectile Dysfunction | 45 (45%) |
| Urinary Tract Infection | 39 (30%) |
| Urinary Retention | 34 (27%) |
| Hematuria | 19 (17%) |
| Miction disturbances | 13 (13%) |
| Urinary Incontinence | 13 (12%) |
| Prostate Infection | 9 (8%) |
| Urinary Frequency | 8 (8%) |
| Ejaculation Disorder | 6 (6%) |
| Urinary Urgency | 5 (5%) |
| Urinary Tract Obstruction | 4 (4%) |
| Urinary Tract Pain | 3 (2%) |
| Testicular Disorder | 3 (2%) |
| Other (1) | 35 (25%) |
(1) includes Gastrointestinal disorders (4), Blader tenesment (3), Renal calculi (2), headache (2), hypotension (2),
{7}------------------------------------------------
Pelvic pain (2), rectal/anal pain (2), Allergic reaction (2), and other with 1 occurrence only throughout the whole 100 patients
Substantial Equivalence
The claim of substantial equivalence of the Focal One to the Ablatherm (K153023 and Sonablate (K160942) is based on the comparison of the indications and intended use, product design and technical characteristics, and performance characteristics.
| Focal One® | Ablatherm® | Sonablate® | Performance Characteristics | ||||
|---|---|---|---|---|---|---|---|
| Subject Device | Imaging modality for localization, treatment and control | Ultrasound | Ultrasound | Ultrasound | |||
| Manufacturer | EDAP | EDAP | SonaCare | Fusion of ultrasound with other imaging modalities (DICOM) | Yes | No | Yes |
| 510(k) No. | In progress | K153023 | K160942 | Probe type | Curved Array | Curved array | Linear Mechanical |
| Product Code | PLP | PLP | PLP | Imaging Frequency | 7 MHz | 7.5 MHz | 4.0 MHz Nominal (3.5-8 MHz Range) |
| Intended Use | Longitudinal Imaging frame rate (typical) | NA (Longitudinal image is reconstructed) | NA (Longitudinal image is reconstructed) | 2 FPS | |||
| Indications for Use | Indicated fortransrectal highintensity focusedultrasound (HIFU)ablation of prostatetissue. | Indicated fortransrectal highintensity focusedultrasound (HIFU)ablation of prostatetissue. | Indicated fortransrectal highintensity focusedultrasound (HIFU)ablation ofprostatic tissue | Transverse Imaging frame rate (typical) | 25 FPS | 25 FPS* | 3 FPS |
| Prescription use | Yes | Yes | Yes | Image size | 8x8cm | 8x8cm | 4.5 x 6.25 cm |
| Minimally invasive | Yes | Yes | Yes | Field of view | 140° | 130° | 112° |
| Outpatient procedures | Yes | Yes | Yes | Ablation modality | HIFU | HIFU | HIFU |
| Anesthesia required | Yes | Yes | Yes | Ablation Frequency | 3.0 MHz | 3.0 MHz | 4.0 MHz |
| Physician training required | Yes | Yes | Yes | Focal Distance | $60 mm \pm 2 mm$32-67 mm | $45 mm \pm 2 mm$ | $30 mm \pm 1 mm$$40 mm \pm 2 mm$ |
| General Description | Probe length | 60.9 | 60.9 mm | 58.7 mm | |||
| System Components | Control module,Computer andperipherals,Endorectal probe,Cooling unit, Probeholder, Ultrasoundscanner, DisposableaccessoriesProbe movementassemblyMovement detector, | Control module,Computer andperipherals.Endorectal probe,Cooling unit,Probe holder,Ultrasound scanner,DisposableaccessoriesProbe momentassemblyMovement detector,Treatment module(patient support), | Control module,Computer andperipheralsEndorectal probe,Cooling unit,Probe holder,UltrasoundscannerDisposableaccessories | Probe diameter | 38.4 | 38.4 mm | 33 mm |
| Patient position | right lateraldecubitus | right lateraldecubitus | lithotomy | Probe neck diameter | 25 mm | 19.5 mm | 18 mm |
| Management of protocols | Pre-set algorithm | Pre-set algorithm | Manual Adjustment |
{8}------------------------------------------------
*Note the Ablatherm Integrated Imaging 510(k) (K153023) listed 5 FPS as the typical Transverse Imaging frame rate. This was a typographical error. The typical Transverse Imaging frame rate should have been listed as 25 FPS.
The claim of substantial equivalence of the Focal One to the Ablatherm (K153023) and Sonablate (K160942) is also based on the comparison of clinical outcomes such as targeted volume as related to adverse events, PSA reductions from baseline, and biopsy results.
The claim of substantial equivalence for the image fusion function of Focal One "Fusion of ultrasound with other imaging modalities (DICOM)" references K172285 for the Ablatherm Fusion variant which was cleared for this feature.
Conclusion
Based on the indications and intended use, device design, performance and conformity with recognized consensus standards, as well as clinical data, the Focal One is substantially equivalent to the Ablatherm® Integrated Imaging (K153023) and the Sonablate® (K160942). The Focal One is as safe and effective as the predicate devices. Minor performance and technological differences between the Focal One and its predicate devices do not present new issues of safety and effectiveness when compared to the predicate devices. In vivo and in vitro testing, clinical testing and validation of the Focal One software confirm that the Focal One performs as intended. Thus, the Focal One is substantially equivalent.
§ 876.4340 High intensity ultrasound system for prostate tissue ablation.
(a)
Identification. A high intensity ultrasound system for prostate tissue ablation is a prescription device that transmits high intensity therapeutic ultrasound energy into the prostate to thermally ablate a defined, targeted volume of tissue, performed under imaging guidance. This classification does not include devices that are intended for the treatment of any specific prostate disease and does not include devices that are intended to ablate non-prostatic tissues/organs.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Characterization of acoustic pressure and power output at clinically relevant levels;
(ii) Measurement of targeting accuracy and reproducibility of high intensity ultrasound output;
(iii) Ultrasound-induced heating verification testing at target and non-target tissues;
(iv) Electrical safety testing; and
(v) Electromagnetic compatibility testing.
(2) Software verification, validation, and hazard analysis must be performed.
(3) The elements of the device that may contact the patient's mucosal tissue must be demonstrated to be biocompatible.
(4) Performance data must demonstrate the sterility of the device components that contact the patient's mucosal tissue.
(5) Performance data must support shelf life by demonstrating continued sterility of the device or the sterile components, package integrity, and device functionality over the identified shelf life.
(6) Performance data must support the instructions for reprocessing all reusable components.
(7)
In vivo testing must demonstrate that the device thermally ablates targeted tissue in a controlled manner without thermal injury to adjacent, non-target tissues.(8) Clinical testing must document the adverse event profile, provide evidence of prostatic ablation, and demonstrate that the device performs as intended under anticipated conditions of use.
(9) Training must be provided so that upon completion of the training program, the physician can:
(i) Use all safety features of the device;
(ii) Accurately target the high intensity ultrasound energy within the desired region of the prostate; and
(iii) Perform the ablation procedure in a manner that minimizes damage to non-target tissues.
(10) Labeling must include:
(i) A section that summarizes the clinical testing results, including the adverse event profile and evidence of prostate ablation achieved; and
(ii) An expiration date or shelf life for single use components.